Mechanism of immunomodulatory drugs in multiple myeloma

Leukemia Research

Volumn 36, Issue 10, 2012, Pages 1218-1224

  Sedlarikova, Lenka ^a   Kubiczkova, Lenka ^a   Sevcikova, Sabina ^a   Hajek, Roman ^a  

^a MASARYK UNIVERSITY   (Czech Republic)

Author keywords

Immunomodulatory drugs; Lenalidomide; Multiple myeloma; Pomalidomide; Thalidomide; Treatment

Indexed keywords

IMMUNOMODULATING AGENT; LENALIDOMIDE; POMALIDOMIDE; THALIDOMIDE;

ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; BONE LESION; BONE MARROW; CANCER SURVIVAL; CELL CYCLE ARREST; CLINICAL PROTOCOL; CYTOKINE RELEASE; DRUG APPROVAL; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; ERYTHEMA NODOSUM LEPROSUM; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOMODULATION; IMMUNOREGULATION; MORNING SICKNESS; MULTIPLE MYELOMA; NATURAL KILLER CELL; NATURAL KILLER T CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; RISK BENEFIT ANALYSIS; SIGNAL TRANSDUCTION; SURVIVAL TIME; T LYMPHOCYTE ACTIVATION; TERATOGENESIS;

ANIMALS; HUMANS; IMMUNOLOGIC FACTORS; MULTIPLE MYELOMA;

EID: 84865190788     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.05.010     Document Type: Review

References (62)

1. Harris N.L., Jaffe E.S., Diebold J., Flandrin G., Muller-Hermelink H.K., Vardiman J., et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999, 17:3835-3849.
2. Anderson K.C., Carrasco R.D. Pathology of myeloma. Annu Rev Pathol Mech Dis 2011, 6:249-274.
3. Hajek R., Krejci M., Pour L., Adam Z. Multiple myeloma. Klinická onkologie 2011, 24:S10-S13.
4. Solly S. Remarks on the pathology of mollities ossium with cases. Med Chir Trans 1844, 27:435-461.
5. Macintyre W. Case of mollities and fragilitas ossium, accompanied with urine strongly charged with animal matter. Med Chir Trans 1850, 33:211-232.
6. Loge J.P., Rundles R.W. Urethane (ethyl carbamate) therapy in multiple myeloma. Blood 1949, 4:201-216.
7. Alexanian R., Haut A., Khan A.U., Lane M., Mckelvey E.M., Migliore P.J., et al. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA 1969, 208:1680-1685.
8. Lokhorst H.M., Sonneveld P., Cornelissen J.J., Joosten P., van Marwijk Kooy M., Meinema J., et al. Induction therapy with vincristine, adriamycin, dexamethasone (VAD) and intermediate-dose melphalan (IDM) followed by autologous or allogeneic stem cell transplantation in newly diagnosed multiple myeloma. Bone Marrow Transplant 1999, 23(February (4)):317-322.
9. Quach H., Ritchie D., Stewart A.K., Neeson P., Harrison S., Smyth M.J., et al. Mechanism of action of immunomodulatory drugs (IMiDs) in multiple myeloma. Leukemia 2010, 24:22-32.
10. Rajkumar S.V. Thalidomide: tragic past and promising future. Mayo Clin Proc 2004, 79:899-903.
11. Singhal S., Mehta J., Desikan R., Ayers D., Roberson P., Eddlemon P., et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999, 341:1565-1571.
12. D'amato R.J., Loughnan M.S., Flynn E., Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994, 91:4082-4085.
13. Davies F.E., Raje N., Hideshima T., Lentszch S., Young G., Tai Y., et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001, 98:210-216.
14. Hideshima T., Chauhan D., Schlossman R., Richardson P., Anderson K.C. The role of tumor necrosis factor α in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene 2001, 20:4519-4527.
15. Iyer C.G.S., Languillon J., Ramanujam K., Tarabini-Castellani G., Terencio D.E., Las Aguas J., et al. WHO co-ordinated short-term double-blind trial with thalidomide in the treatment of acute lepra reactions in male lepromatous patients. Bull World Health Organ 1971, 45:719-732.
16. Zeldis J.B., Williams B.A., Thomas S.D., Elsayed M.E. S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide. Clin Ther 1999, 21:319-330.
17. Vogelsang G.B., Farmer E.R., Hess A.D., Altamonte V., Beschorner W.E., Jabs D.A., et al. Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med 1992, 326:1055-1058.
18. Kotla V., Goel S., Nischal S., Heuck C.H., Vivek K., Das B., et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol 2009, 2.
19. Muller G.W., Chen R., Huang S.Y., Corral L.G., Wong L.M., Patterson R.T., et al. Amino-substituted thalidomide analogs: potent inhibitors of TNF-α production. Bioorg Med Chem Lett 1999, 9:1625-1630.
20. Dredge K., Marriott J.B., Macdonald C.D., Man H.W., Chen R., Muller G.W., et al. Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer 2002, 87:1166-1172.
21. + tumor cells. Clin Cancer Res 2008, 14:4650-4657.
22. Bjorklund C.C., Ma W., Wang Z.Q., Davis R.E., Kuhn D.J., Kornblau S.M., et al. Evidence of a role for activation of Wnt/β-catenin signaling in the resistance of plasma cells to lenalidomide. J Biol Chem 2011, 286:11009-11020.
23. Hideshima T., Chauhan D., Shima Y., Raje N., Davies F.E., Gupta D., et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000, 96:2943-2950.
24. WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism. Cancer Res 2009, 69:7347-7356.
25. + progenitor cells. Cancer Res 2007, 67:746-755.
26. Gandhi A.K., Kang J., Capone L., Parton A., Wu L., Zhang L.H., et al. Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function. Curr Cancer Drug Targets 2010, 10:155-167.
27. Wang C.Y., Mayo M.W., Korneluk R.G., Goeddel D.V., Baldwin A.S.J. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 1998, 281:1680-1683.
28. Mitsiades N., Mitsiades C.S., Poulaki V., Anderson K.C., Treon S.P. Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells. Blood 2002, 99:2162-2171.
29. Mitsiades N., Mitsiades C.S., Poulaki V., Chauhan D., Richardson P.G., Gu X., et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002, 99:4525-4530.
30. Mitsiades C.S., Mitsiades N., Poulaki V., Schlossman R., Akiyama M., et al. Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene 2002, 21:5673-5683.
31. Lopez Girona A., Heintel D., Zhang L.H., Mendy D., Gaidarova S., Bradz H., et al. Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response. Br J Haematol 2011, 154:325-336.
32. Chang X.B., Stewart A.K. What is the functional role of the thalidomide binding protein cereblon?. Int J Biochem Mol Biol 2011, 2:287-294.
33. Haslett P.A.J., Corral L.G., Albert M., Kaplan G. Thalidomide costimulates primary T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med 1998, 187:1885-1892.
34. Schafer P.H., Gandhi A.K., Loveland M.A., Chen R.S., Man H., Schnetkamp P.P.M., et al. Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. J Pharmacol Exp Ther 2003, 305:1222-1232.
35. Görgün G., Calabrese E., Soydan E., Hideshima T., Perrone G., Bandi M., et al. Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marro accessory cells in multiple myeloma. Blood 2010, 116:3227-3237.
36. Leblanc R., Hideshima T., Catley L.P., Shringarpure R., Burger R., Mitsiades N., et al. Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood 2004, 103:1787-1790.
37. Hayashi T., Hideshima T., Akiyama M., Podar K., Yasui H., Raje N., et al. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol 2005, 128:192-203.
38. + natural killer T cells using α-galactosyl ceramide-pulsed dendritic cells. J Immunol Methods 2003, 272:147-159.
39. Chang D.H., Liu N., Klimek V., Hassoun H., Mazumder A., Nimer S.D., et al. Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic aplications. Blood 2006, 108:618-621.
40. Muthu Raja K.R., Kovářová L., Štossová J., Hájek R. Flow cytometric phenotyping and analysis of T regulatory cells in multiple myeloma patients. Klinická onkologie 2011, 24:S30-S33.
41. Galustian C.H., Meyer B., Labarthe M., Dredge K., Klaschka D., Henry J., et al. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother 2009, 58:1033-1045.
42. Muthu Raja K.R., Kovářová L., Hájek R. Induction by lenalidomide and dexamethasone combination increases regulatory cells of patients with previously untreated multiple myeloma. Leuk Lymphoma 2012, [Epub ahead of print].
43. Gupta R., Ganeshan P., Hakim M., Verma R., Sharma A., Kumar L. Significantly reduced regulatory T cell population in patients with untreated multiple myeloma. Leuk Res 2011, 35:874-878.
44. Muthu Raja K.R., Hájek R. Regulatory cells and multiple myeloma. Multiple myeloma-an overview 2012, 33-60. InTech, Rijeka, Croatia. A. Gupta (Ed.).
45. Dredge K., Horsfall R., Robinson S.P., Zhang L.H., Lu L., Tang Y., et al. Orally administred lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvas Res 2005, 69:56-63.
46. Esser S., Lampugnani M.G., Corada M., Dejana E., Risau W. Vascular endothelial growth factor induces VE-cadherin tyrosine phosphorylation in endothelial cells. J Cell Sci 1998, 111:1853-1865.
47. De Luisi A., Ferrucci A., Coluccia A.M.L., Ria R., Moschetta M., De Luca E., et al. Lenalidomide restrains motility and overangiogenic potential of bone marrow endothelial cells in patients with active multiple myeloma. Clin Cancer Res 2011, 17:1935-1946.
48. Dankbar B., Padró T., Leo R., Feldmann B., Kropff M., Mesters R.M., et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 2000, 95:2630-2636.
49. Gupta D., Treon S.P., Shima Y., Hideshima T., Podar K., Tai Y.T., et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 2001, 15:1950-1961.
50. Lu L., Payvandi F., Wu L., Zhang L.H., Hariri R.J., Man H.W., et al. The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. Microvasc Res 2009, 77:78-86.
51. 2 in a murine model of inflammation: possible role of cyclooxygenase-2. Proc Natl Acad Sci USA 1996, 93:4885-4890.
52. Payvandi F., Wu L., Haley M., Schafer P.H., Zhang L.H., Chen R.S., et al. Immunomodulatory drugs inhibit expression of cyclooxygenase-2 from TNF-α, IL-1β, and LPS-stimulated human PBMC in a partially IL-10-dependent manner. Cell Immunol 2004, 230:81-88.
53. Sampaio E.P., Sarno E.N., Galilly R., Cohn Z.A., Kaplan G. Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes. J Exp Med 1991, 173:699-703.
54. Moreira A.L., Sampaio E.P., Zmuidzinas A., Frindt P., Smith K.A., Kaplan G., et al. Thalidomide exerts its inhibitory action on tumor necrosis factor α by enhancing mRNA degradation. J Exp Med 1993, 177:1675-1680.
55. Keifer J.A., Guttridge D.C., Ashburner B.P., Baldwin A.S.J. Inhibition of NF-κB activity by thalidomide through suppression of IκB kinase activity. J Biol Chem 2001, 276:22382-22387.
56. Corral L.G., Haslett P.A., Muller G.W., Chen R., Wong L., Ocampo C.J., et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-α. J Immunol 1999, 163:380-386.
57. Breitkreutz I., Raab M.S., Vallet S., Hideshima T., Raje N., Mitsiades C., et al. Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia 2008, 22:1925-1932.
58. Rieman D.J., McClung H.A., Dodds R.A., Hwang S.M., Lark M.W., Holmes S., et al. Biosynthesis and processing of cathepsin K in cultured human osteoclasts. Bone 2001, 28:282-289.
59. Anderson G., Gries M., Kurihara N., Honjo T., Anderson J., Donnenberg V., et al. Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. Blood 2006, 107:3098-3105.
60. Muthu Raja K.R., Kovářová L., Hájek R. Review of phenotypic markers used in flow cytometric analysis of MGUS and MM, and applicability of flow cytometry in other plasma cell disorders. Br J Haematol 2010, 149:334-351.
61. Geitz H., Handt S., Zwingenberger K. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology 1996, 31:213-221.
62. Oliveira A.M., Maria D.A., Metzger M., Linardi C., Giorgi R.R., Moura F., et al. Thalidomide treatment down-regulates SDF-1α and CXCR4 expression in multiple myeloma patients. Leuk Res 2009, 33:970-973.